Phase Ib/II Study of Selinexor in Combination with Carfilzomib, subcutaneous Isatuximab administered via investigational device, and Dexamethasone (SCID) for Patients with Relapsed and/or Relapsed Refractory Multiple Myeloma
Current Trials
Our Network
Our Story
